Search
Search Constraints
You searched for: Author/Creator Lalami, Yassine- Lalami, Yassine [remove] 5
- 616.994 3
- Oncology -- Periodicals 3
- 615.580724 1
- 617.51059 1
- ABCC1/MRP ATP binding cassette subfamily C member 1/ multidrug resistance protein -- ABVD doxorubicine-bleomycin-vinblastine-dacarbazine -- AC doxorubicin-cyclophosphamide -- ANC absolute neutrophil count -- ASCO American Society of Clinical Oncology -- AUC area under the curve -- BMI body mass index -- BSA body surface area -- CI confidence interval -- CIN chemotherapy-induced neutropenia -- CRC colorectal cancers -- CTLA-4 cytotoxic T-lymphocyte antigen 4 -- CYP cytochrome P -- CYP2D6 cytochrome P450 2D6 -- DFS disease-free survival -- DI dose-intensity -- DID dose intensity of doxorubicin -- DLBCL diffuse large B cell lymphoma -- DNA deoxyribonucleic acid -- DPYD dihydropyrimidine deshydrogenase -- Doc docetaxel -- EGFR epidermal growth factor receptor -- EOC epithelial ovarian cancer -- EORTC European Organization for Research and Treatment of Cancer -- ERCC excision repair cross complementing -- ESBC early stage breast cancer -- FEC fluorouracil-epirubicin-cyclophosphamide -- FGFR fibroblast growth factor receptor -- FLT-3 Fms-like tyrosine kinase 3 (FLT-3 -- FN febrile neutropenia -- FOLFIRI irinoteca-elvorin-fluorouracil -- FOLFOX oxaliplatin-elvorin-fluorouracil -- G-CSF granulocyte colony stimulating factors -- GSTM1 glutathione S-transferase Mu 1 -- HER2 human epidermal receptor 2 -- HL Hodgkin lymphoma -- HR hazard ratio -- IROX irinotecan-oxaliplatin -- MBL2 mannose-binding lectin 2 -- MDM SNP309 murine double minute single nucleotide polymorphism -- MMP-9 matrix metalloprotease type 9 -- mTOR mammalian target of rapamycin -- NCCN National Comprehensive Cancer Network -- NHL non-Hodgkin lymphoma -- NSCLC non-small cell lung cancer -- OR odds ratio -- OS overall survival -- PFS progression free survival -- PD pharmacodynamic -- PG pharmacogenomic -- PI3K/AKT phosphatidylinositol-3-kinase and protein kinase B -- PP primary prophylaxis -- PK pharmacokinetic -- QoL quality of life -- R-CHOP rituximab-cyclophosphamide-doxorubicin-vincristine-prednisone -- RCTs randomized controlled trials -- RDI relative dose intensity -- RR risk ratio -- SN severe neutropenia -- SNPs single nucleotide polymorphisms -- TAC docetaxel-doxorubicin-cyclophosphamie -- TC docetaxel-cyclophosphamide -- TCb docetaxel-carboplatin -- TTP time to tumor progression -- TP53 R72P TP53 gene polymorphism resulting in arginine (R) to proline (P) at codon 72 -- TPMP thiopurine Methyltransferase -- UGT1A1 UDP-glycosyltransferase 1 polypeptide A1 -- UGT2B7 UDP-glucuronosyltransferase 2b7 1
- Cancérologie -- Périodiques 1
- Chemotherapy -- Neutropenia -- Febrile neutropenia -- Relative dose intensity -- Pharmacogenetics -- Pharmacogenomics 1
- Clinical trials -- Periodicals 1
- Drug development -- Periodicals 1
- Drugs -- Testing -- Periodicals 1